Edition:
United Kingdom

Shionogi & Co Ltd (4507.T)

4507.T on Tokyo Stock Exchange

6,398JPY
5:15am BST
Change (% chg)

¥-24 (-0.37%)
Prev Close
¥6,422
Open
¥6,395
Day's High
¥6,429
Day's Low
¥6,353
Volume
512,400
Avg. Vol
1,175,199
52-wk High
¥7,796
52-wk Low
¥5,410

Latest Key Developments (Source: Significant Developments)

Shionogi & Co: Bought Back 7.35 Million Shares For About 50 Billion Yen Through Dec 18
Friday, 21 Dec 2018 

Dec 21 (Reuters) - Japan's Shionogi & Co Ltd <4507.T>::BOUGHT BACK 7.35 MILLION SHARES FOR ABOUT 50 BILLION YEN THROUGH DEC 18.  Full Article

Tetra Discovery Partners And Shionogi & Co., Ltd. Collaborate On Bpn14770 Development And Commercialization
Tuesday, 18 Dec 2018 

Dec 18 (Reuters) - Shionogi & Co Ltd <4507.T>::TETRA DISCOVERY PARTNERS AND SHIONOGI & CO., LTD. COLLABORATE ON BPN14770 DEVELOPMENT AND COMMERCIALIZATION.SHIONOGI & CO LTD - DEAL VALUED AT POTENTIAL $160 MILLION PLUS ROYALTIES, INCLUDING $5 MILLION IN UPFRONT PAYMENTS AND $35 MILLION IN EQUITY INVESTMENT.SHIONOGI & CO LTD - SHIONOGI GAINS REGIONAL LICENSE TO ALZHEIMER'S DRUG CANDIDATE FOR JAPAN, KOREA AND TAIWAN.SHIONOGI & CO - TETRA TO ALSO BE ELIGIBLE TO GET UP TO ADDITIONAL $120 MILLION IN DEVELOPMENT, COMMERCIALIZATION MILESTONES, AS WELL AS ROYALTIES ON SALES.SHIONOGI & CO LTD - FURTHER FINANCIAL DETAILS OF AGREEMENT WERE NOT DISCLOSED..SHIONOGI & CO - IN EXCHANGE FOR GRANTING CO DEVELOPMENT RIGHTS TO BPN14770 IN JAPAN, TAIWAN, KOREA, TETRA RECEIVED $40 MILLION IN COMBINED UPFRONT FUNDING.  Full Article

Shionogi & Co Bought Back Own Shares For 10.22 Billion Yen In November
Friday, 14 Dec 2018 

Shionogi & Co Ltd <4507.T>::BOUGHT BACK OWN SHARES FOR 10.22 BILLION YEN IN NOVEMBER.  Full Article

SHIONOGI increases voting power in UMN Pharma to 20.3 pct
Wednesday, 31 Oct 2018 

Oct 31(Reuters) - UMN Pharma Inc <4585.T>:Says SHIONOGI & CO LTD <<<4507.T>>> increases voting power in UMN Pharma to 20.3 percent from 4.7 percent, effective Oct. 31 .  Full Article

R&I affirms Shionogi's rating at "A+" and changes outlook to positive -R&I
Friday, 26 Oct 2018 

Oct 26(Reuters) - Shionogi & Co Ltd <4507.T>:Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A+" -R&I.Rating outlook changes to positive from stable -R&I.  Full Article

Shionogi announces FDA approval of Baloxavir Marboxil for treatment of acute, uncomplicated influenza
Thursday, 25 Oct 2018 

Oct 25 (Reuters) - Shionogi & Co Ltd <4507.T>:Says the company announced today that, after completing a priority review, the United States Food and Drug Administration (FDA) has approved XOFLUZATM(baloxavir marboxil) for the treatment of acute, uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours.  Full Article

U.S. FDA Says Granted Approval Of New Influenza Drug To Shionogi & Co
Wednesday, 24 Oct 2018 

Oct 24 (Reuters) - U.S. Food and Drug Administration::FDA APPROVES NEW DRUG TO TREAT INFLUENZA.FDA - APPROVED XOFLUZA FOR TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 12 YRS & OLDER WHO HAVE BEEN SYMPTOMATIC FOR NO MORE THAN 48 HOURS.FDA - GRANTED APPROVAL OF XOFLUZA TO SHIONOGI & CO.  Full Article

Shionogi announces U.S. availability of Mulpleta®
Friday, 31 Aug 2018 

Aug 31(Reuters) - Shionogi & Co Ltd <4507.T>:Says it announced today that Mulpleta® (lusutrombopag), for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo a procedure, is now available throughout the U.S..  Full Article

Shionogi Announces FDA Approval Of Mulpleta (Lusutrombopag)
Wednesday, 1 Aug 2018 

Aug 1 (Reuters) - Shionogi & Co Ltd <4507.T>::SHIONOGI ANNOUNCES FDA APPROVAL OF MULPLETA® (LUSUTROMBOPAG).SHIONOGI - FDA APPROVED MULPLETA FOR TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC LIVER DISEASE SCHEDULED TO UNDERGO A PROCEDURE.  Full Article

Shionogi & Co Ltd Says To Buy Back Up To 2.7 Percent Of Own Shares Worth 50 Billion Yen
Monday, 30 Jul 2018 

July 30 (Reuters) - Shionogi & Co Ltd <4507.T>::SHIONOGI & CO LTD SAYS TO BUY BACK UP TO 2.7 PERCENT OF OWN SHARES WORTH 50 BILLION YEN.  Full Article

Japanese drugmaker Shionogi sees record profit on royalty income

TOKYO Japanese drugmaker Shionogi & Co Ltd forecast a 6.1 percent jump in full-year operating profit to what would be its fifth straight record high, underpinned by strong royalty income from its HIV drugs.